FI4058060T3 - Tyypin i interferonin esto systeemisen lupus erythematosuksen hoidossa - Google Patents
Tyypin i interferonin esto systeemisen lupus erythematosuksen hoidossa Download PDFInfo
- Publication number
- FI4058060T3 FI4058060T3 FIEP20804531.0T FI20804531T FI4058060T3 FI 4058060 T3 FI4058060 T3 FI 4058060T3 FI 20804531 T FI20804531 T FI 20804531T FI 4058060 T3 FI4058060 T3 FI 4058060T3
- Authority
- FI
- Finland
- Prior art keywords
- ifnr
- inhibitor
- subject
- use according
- type
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Claims (8)
1. Tyypin | IFN-reseptorin (IFNR) estäjä käytettäväksi menetelmässä systeemisen punalupus erythematosuksen (SLE) hoitamiseksi sen tarpeessa olevalla hoidettavalla, jolloin menetelmä käsittää tyypin | interferoni (IFN) - reseptorin (IFNR) estäjän antamisen terapeuttisesti tehokkaana määränä hoidettavalle, jolloin hoidettavalla on lähtötilanteessa alhainen tyypin | IFN- geeniosa (IFNGS), jolloin IFNR:n estäjä on vähentää SLE:n tautiaktiivisuutta hoidettavalla, jolloin IFNR:n estäjä on anifrolumabi ja jolloin hoidettavan IFNGS lähtötilanteessa on mitattavissa 4 geenin kvantitatiivisella polymeraasiketjureaktioon perustuvalla testillä, jolloin kyseinen testi mittaa IFI27-, IF144-, IFI44L- ja RSAD2-ilmentymistä hoidettavan kokoveressä.
2. IFNR:n estäjä jonkin edellisen patenttivaatimuksen mukaiseen käyttöön, — jolloin hoidettavan SLE-tautiaktiivisuuden vähentäminen käsittää BILAG-pohjaisen lupuksen yhdistelmäarvioinnin (BICLA) vasteen hoidettavalla.
3. IFNR:n estäjä jonkin edellisen patenttivaatimuksen mukaiseen käyttöön, jolloin hoidettavalla on keskivaikea tai vaikea SLE.
4. IFNR:n estäjä patenttivaatimuksen 5 mukaiseen käyttöön, jolloin menetelmä käsittää IFNR:n estäjän antamisen 300 mg:n annoksena hoidettavalle.
5. IFNR:n estäjä patenttivaatimuksen 5 tai 6 mukaiseen käyttöön, joka käsittää IFNR:n estäjän annoksen antamisen hoidettavalle 4 viikon välein.
6. IFNR:n estäjä jonkin edellisen patenttivaatimuksen mukaiseen käyttöön, jolloin IFNR:n estäjää annetaan hoidettavalle laskimoon.
7. IFNR:n estäjä jonkin patenttivaatimuksen 1-5 mukaiseen käyttöön, jolloin IFNR:n estäjää annetaan hoidettavalle ihonalaisesti.
2 EP4 058 060
8. IFNR:n estäjä jonkin edellisen patenttivaatimuksen mukaiseen käyttöön, jolloin hoidettava on positiivinen dsDNA-, tuma- tai Smith-vasta-aineille lähtötilanteessa.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933672P | 2019-11-11 | 2019-11-11 | |
| US202063031848P | 2020-05-29 | 2020-05-29 | |
| US202063089345P | 2020-10-08 | 2020-10-08 | |
| PCT/EP2020/081770 WO2021094378A1 (en) | 2019-11-11 | 2020-11-11 | Type i interferon inhibition in systemic lupus erythematosus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4058060T3 true FI4058060T3 (fi) | 2025-03-21 |
Family
ID=73344065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20804531.0T FI4058060T3 (fi) | 2019-11-11 | 2020-11-11 | Tyypin i interferonin esto systeemisen lupus erythematosuksen hoidossa |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220396630A1 (fi) |
| EP (2) | EP4494712A3 (fi) |
| JP (1) | JP2023501462A (fi) |
| KR (1) | KR102766960B1 (fi) |
| CN (1) | CN114728059A (fi) |
| AU (1) | AU2020382850B2 (fi) |
| CA (1) | CA3159568A1 (fi) |
| DK (1) | DK4058060T3 (fi) |
| ES (1) | ES3021878T3 (fi) |
| FI (1) | FI4058060T3 (fi) |
| HU (1) | HUE070947T2 (fi) |
| IL (1) | IL292706A (fi) |
| PL (1) | PL4058060T3 (fi) |
| PT (1) | PT4058060T (fi) |
| TW (1) | TW202133877A (fi) |
| WO (1) | WO2021094378A1 (fi) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202237647A (zh) * | 2020-10-08 | 2022-10-01 | 瑞典商阿斯特捷利康公司 | 狼瘡發作之治療 |
| KR20230110304A (ko) * | 2020-11-18 | 2023-07-21 | 아스트라제네카 아베 | 스테로이드 절약 |
| SMT202300382T1 (it) | 2021-04-23 | 2024-01-10 | Astrazeneca Ab | Regime di dosaggio anti-ifnar1 per iniezione sottocutanea |
| CN113278071B (zh) * | 2021-05-27 | 2021-12-21 | 江苏荃信生物医药股份有限公司 | 抗人干扰素α受体1单克隆抗体及其应用 |
| EP4545090A1 (en) * | 2023-10-27 | 2025-04-30 | Universität Leipzig | Interferon-a receptor immune modulator for use as a medicament |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2643237T3 (es) | 2004-06-21 | 2017-11-21 | E. R. Squibb & Sons, L.L.C. | Anticuerpos del receptor 1 de interferón alfa y sus usos |
| MX2010008578A (es) | 2008-02-08 | 2010-11-10 | Medimmune Llc | Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc. |
| SMT201700063T1 (it) | 2009-09-03 | 2017-03-08 | Medimmune Llc | Diagnosi di interferoni di tipo 1 |
| SI3769781T1 (sl) * | 2015-08-19 | 2023-06-30 | Astrazeneca Ab | Stabilna formulacija proti-IFNAR1 |
| EP3924383A1 (en) * | 2019-02-15 | 2021-12-22 | Astrazeneca AB | Type i interferon-mediated disorders |
-
2020
- 2020-11-11 DK DK20804531.0T patent/DK4058060T3/da active
- 2020-11-11 EP EP24205849.3A patent/EP4494712A3/en not_active Withdrawn
- 2020-11-11 WO PCT/EP2020/081770 patent/WO2021094378A1/en not_active Ceased
- 2020-11-11 TW TW109139396A patent/TW202133877A/zh unknown
- 2020-11-11 EP EP20804531.0A patent/EP4058060B1/en active Active
- 2020-11-11 ES ES20804531T patent/ES3021878T3/es active Active
- 2020-11-11 KR KR1020227018548A patent/KR102766960B1/ko active Active
- 2020-11-11 JP JP2022526517A patent/JP2023501462A/ja active Pending
- 2020-11-11 CN CN202080077901.4A patent/CN114728059A/zh active Pending
- 2020-11-11 PL PL20804531.0T patent/PL4058060T3/pl unknown
- 2020-11-11 CA CA3159568A patent/CA3159568A1/en active Pending
- 2020-11-11 US US17/755,801 patent/US20220396630A1/en not_active Abandoned
- 2020-11-11 FI FIEP20804531.0T patent/FI4058060T3/fi active
- 2020-11-11 AU AU2020382850A patent/AU2020382850B2/en not_active Ceased
- 2020-11-11 PT PT208045310T patent/PT4058060T/pt unknown
- 2020-11-11 IL IL292706A patent/IL292706A/en unknown
- 2020-11-11 HU HUE20804531A patent/HUE070947T2/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021094378A9 (en) | 2021-07-29 |
| PT4058060T (pt) | 2025-04-24 |
| KR102766960B1 (ko) | 2025-02-11 |
| KR20220099985A (ko) | 2022-07-14 |
| EP4058060A1 (en) | 2022-09-21 |
| HUE070947T2 (hu) | 2025-07-28 |
| DK4058060T3 (da) | 2025-03-17 |
| ES3021878T3 (en) | 2025-05-27 |
| EP4494712A3 (en) | 2025-03-26 |
| CA3159568A1 (en) | 2021-05-20 |
| EP4058060B1 (en) | 2025-02-19 |
| IL292706A (en) | 2022-07-01 |
| PL4058060T3 (pl) | 2025-07-28 |
| WO2021094378A1 (en) | 2021-05-20 |
| US20220396630A1 (en) | 2022-12-15 |
| CN114728059A (zh) | 2022-07-08 |
| EP4494712A2 (en) | 2025-01-22 |
| JP2023501462A (ja) | 2023-01-18 |
| AU2020382850A1 (en) | 2022-06-23 |
| TW202133877A (zh) | 2021-09-16 |
| AU2020382850B2 (en) | 2025-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abbasi et al. | Strategies toward rheumatoid arthritis therapy; the old and the new | |
| Terrier et al. | Efficacy and tolerability of rituximab with or without PEGylated interferon alfa‐2b plus ribavirin in severe hepatitis C virus–related vasculitis: a long‐term followup study of thirty‐two patients | |
| Lawitz et al. | A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1 | |
| Liesegang | Herpes zoster virus infection | |
| Srisupa-Olan et al. | Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders | |
| Ogawa et al. | Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy | |
| IL274272B1 (en) | A safe and effective method for treating psoriatic arthritis with a specific anti-IL23 antibody | |
| Lawitz et al. | Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection | |
| Adinolfi et al. | Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia | |
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| Benitah et al. | The use of biologic agents in the treatment of ocular manifestations of Behcet’s disease | |
| Megna et al. | IL-23 inhibitors in psoriasis: what have we learnt so far? | |
| Furber et al. | Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a | |
| Mackensen et al. | Interferons and their potential in the treatment of ocular inflammation | |
| Musallam et al. | Steroids for deteriorating herpes simplex virus encephalitis | |
| Yao et al. | Tranylcypromine reduces herpes simplex virus 1 infection in mice | |
| Garbarino et al. | ABS0821 ANIFROLUMAB IN CUTANEOUS AND SYSTEMIC LUPUS ERYTHEMATOSUS: A REAL-LIFE EXPERIENCE | |
| Nicoletta et al. | Management of psoriatic patients in biologic treatment associated with infectious comorbidities | |
| Janodia et al. | Guttate psoriasis following COVID-19 infection | |
| Martín et al. | A recombinant adenovirus expressing ovine interferon tau prevents influenza virus-induced lethality in mice | |
| Soliman et al. | Predictors of sustained virological response in chronic hepatitis C patients treated with current direct acting antiviral drugs | |
| Bain et al. | Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naive patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa | |
| Lyakhovitsky et al. | Dermatomyositis–lupuslike syndrome overlap under treatment with etanercept for rheumatoid arthritis | |
| Revel et al. | Interferons: cytokines in autoimmunity | |
| Poordad et al. | CONCOMITANT MEDICATION USE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY: 937 |